Anixa Biosciences (ANIX) Amortization - Intangibles (2014 - 2019)
Anixa Biosciences' (ANIX) quarterly Amortization - Intangibles came in at $41875.0 in Q3 2019, down 48.51% YoY from $81324.0 in Q3 2018, and down 66.67% on a QoQ basis from $125625.0 in Q2 2019.
Anixa Biosciences (ANIX) Amortization - Intangibles (2014 - 2019) Analysis & Trends
Anixa Biosciences (ANIX) has 6 years of Amortization - Intangibles data on file, last reported at $41875.0 in Q3 2019.
- Quarterly Amortization - Intangibles fell 48.51% year-over-year to $41875.0 in Q3 2019, while the trailing twelve-month figure through Oct 2019 was $418750.0 (up 28.73% YoY) and the FY2019 annual result came in at $418750.0, up 28.73% from the prior year.
- Amortization - Intangibles retreated to $41875.0 in Q3 2019, from $125625.0 in the prior quarter.
- In the past five years, Amortization - Intangibles ranged from a high of $251250.0 in Q1 2019 to a low of $41875.0 in Q3 2019.
- A 5-year average of $90522.6 and a median of $81324.0 in 2015 frame the typical range for Amortization - Intangibles.
- The widest YoY moves for Amortization - Intangibles: up 208.95% in 2019, down 48.51% in 2019.
- Tracing ANIX's Amortization - Intangibles over 5 years: stood at $81319.0 in 2015, then grew by 0.01% to $81324.0 in 2016, then dropped by 0.0% to $81323.0 in 2017, then climbed by 0.0% to $81324.0 in 2018, then sank by 48.51% to $41875.0 in 2019.
- The last three Amortization - Intangibles figures came in at $41875.0 (Q3 2019), $125625.0 (Q2 2019), and $251250.0 (Q1 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2019 | 41,875.00 |
| Apr 30, 2019 | 125,625.00 |
| Jan 31, 2019 | 251,250.00 |
| Oct 31, 2018 | 81,324.00 |
| Jul 31, 2018 | 81,324.00 |
| Apr 30, 2018 | 81,324.00 |
| Jan 31, 2018 | 81,324.00 |
| Oct 31, 2017 | 81,323.00 |
| Jul 31, 2017 | 81,325.00 |
| Apr 30, 2017 | 81,324.00 |
| Jan 31, 2017 | 81,324.00 |
| Oct 31, 2016 | 81,324.00 |
| Jul 31, 2016 | 81,324.00 |
| Apr 30, 2016 | 81,324.00 |
| Jan 31, 2016 | 81,324.00 |
| Oct 31, 2015 | 81,319.00 |
| Jul 31, 2015 | 81,324.00 |
| Apr 30, 2015 | 81,324.00 |
| Jan 31, 2015 | 81,324.00 |
| Oct 31, 2014 | 81,324.00 |